Home › Medications › Mounjaro
Mounjaro
Once-weekly tirzepatide for type 2 diabetes — and powerful weight loss.
Mounjaro is a once-weekly injectable form of tirzepatide, FDA-approved for type 2 diabetes. Its dual GIP/GLP-1 action produces strong blood-sugar and weight effects.
Key facts
- Drug: tirzepatide (dual GIP/GLP-1)
- Dose: up to 15 mg weekly
- Approved for: type 2 diabetes
Mounjaro and weight loss
The weight-loss-approved version of tirzepatide is Zepbound — same molecule, different label. Tirzepatide leads the category in average weight loss (see Mounjaro vs Ozempic).
Side effects
Mostly GI symptoms early on; boxed thyroid C-cell tumor warning; cautions for pancreatitis, gallbladder disease, and low blood sugar with certain diabetes medications.
Curious about tirzepatide?
Check your eligibility with a licensed provider — free and online.
Check Your EligibilityRelated
This page is general education only, not medical advice, and does not create a nurse-patient relationship. GLP-1 medications are prescription drugs with real risks and a boxed warning for thyroid C-cell tumors; they are not right for everyone. Compounded medications are not FDA-approved. Consult a licensed provider. See our medical disclaimer.